Eptifibatide

Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Treatment with eptifibatide is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days, Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy, Major surgery within the preceding 6 weeks, History of stroke within 30 days or any history of hemorrhagic stroke, Current or planned administration of another parenteral GP IIb/IIIa inhibitor, Dependency on renal dialysis…

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT., Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI).

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding Bleeding and hypotension are the most commonly reported adverse reactions. To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

29 products from 15 makers in the NepalDoc medicine catalog use this generic:

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Storage Vials should be stored refrigerated at 2° to 8°C (36° to 46°F). Storage* for a period not to exceed 2 months. Protect from light until administration.

Storage information from the U.S. FDA-approved label.